In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QuantuMDx Group Ltd.

Point-of-care assays support personalized medicine

This article was originally published in Start Up

Executive Summary

QuantuMDx Group Ltd. is developing handheld and portable low-cost diagnostic, genomic sequencing, and proteomic platforms that it thinks will promote the practice of personalized medicine in both developed and developing countries. The company aims to create devices that can provide results within minutes at point-of-care without the need for complex sample preparation processes, and that can integrate with mobile apps for ongoing patient support and education.

You may also be interested in...



Gadeta BV: Using T-Cells To Target Metabolic Dysregulation In Cancer

Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.

PeptiMimesis

PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways

Redx Pharma PLC

Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel